Top Abstract Purchase Related
Home
>
Node
>
Subnode

Single-agent gemcitabine versus cisplatin/etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer

Manegold, C.

Seminars in Oncology 25(4 Suppl 9: 18-22

1998

ISSN/ISBN: 0093-7754
PMID: 9728580
Document Number: 493273
Non-small cell lung cancer (NSCLC) remains a malignancy that is refractory to most currently available chemotherapeutic agents. The most frequently used systemic therapy is cisplatin-based combination therapy, which is not always suitable for patients with stage IV disease because of toxicity. Thus, any single agent with a good patient tolerability profile would be a useful alternative for those patients for whom the main purpose of treatment is palliation. The novel nucleoside analog gemcitabine has proven single-agent activity in patients with NSCLC, with consistent response rates of 20% and above. This report reviews two randomized phase II studies of single-agent gemcitabine versus cisplatin/etoposide in patients with advanced NSCLC.

Document emailed within 1 workday
Secure & encrypted payments

Lee, H-W.; Choi, J-H.; Lim, H-Y.; Park, J.S.; Kim, H.C.; Kang, S.; Oh, Y.T.; Chun, M.; Sheen, S.S.; Oh, Y.J.; Park, K.J.; Hwang, S.C. 2006: The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer -- single institution retrospective analysis Neoplasma 53(1): 30-36
Thongprasert, S.; Chewaskulyong, B. 2004: Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer Journal of the Medical Association of Thailand 87(10): 1162-1167
Ettinger, D.S. 2000: Gemcitabine/Alimta in locally advanced or metastatic non-small-cell lung cancer Oncology 14(7 Suppl 4: 49-52
Le Chevalier, T. 1996: Single-agent activity of gemcitabine in advanced non-small cell lung cancer Seminars in Oncology 23(5 Suppl 10: 36-42
Boven, E.; Tierie, A.H.; Stam, J.; Pinedo, H.M. 1988: Combined radiation therapy and daily low-dose cisplatin for inoperable, locally advanced non-small cell lung cancer: results of a phase Ii trial Seminars in Oncology 15(6 Suppl 7: 18-19
Splinter, T.; Kok, T.; Kho, S.; Lameris, H.; ten Kate, F.; Dalesio, O.; Dolman, B.; Palmen, F.; Bouvy, J.; Burghouts, J. 1986: A multicenter phase Ii trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer Seminars in Oncology 13(3 Suppl 3: 97-103
Gatzemeier, U.; Manegold, C.; Eberhard, W.; Wilke, H.J.; Chomy, F.; Chomy, P.; Khayat, D.; Blatter, J.; Seeber, S.; Drings, P. 1998: Ifosfamide and gemcitabine: a phase Ii trial in advanced inoperable non-small cell lung cancer Seminars in Oncology 25(1 Suppl 2: 15-18
Thongprasert, S.; Chewaskulyong, B.; Pothirat, C. 2001: Combination of gemcitabine and cisplatin in advanced non-small cell lung cancer Journal of the Medical Association of Thailand 84(3): 397-401
Wang, L.; Liao, M-Lin.; Li, L-Yun.; Wan, H-Ying.; Xu, N.; Liu, J-Wei.; Liang, H-Jie. 2004: Clinical benefit of gemcitabine plus cisplatin 3-week regimen for patients with advanced non-small cell lung cancer: a prospective observational study Chinese Medical Journal 117(11): 1607-1610
Perez, E.A.; Gandara, D.R. 1994: Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer Seminars in Oncology 21(3 Suppl 4: 2-5
Wolf, H.; Jassem, E.; Cynowska, B.ła.; Damps, I.; Mierzejewska, E.; Słomiński, J.M. 2002: Chemotherapy of advanced non-small cell lung cancer with the combination of gemcitabine and cisplatin Pneumonologia i Alergologia Polska 70(1-2): 44-51
Bianco, V.; Rozzi, A.; Tonini, G.; Santini, D.; Magnolfi, E.; Vincenzi, B.; D'Angelillo, R.; Marchei, P. 2002: Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): a phase Ii study Anticancer Research 22(5): 3053-3056
Bunn, P.A. 1999: Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer Seminars in Oncology 26(1 Suppl 4: 25-30
Shirinian, M.; Lee, J.S.; Dhingra, H.H.; Greenberg, J.; Hong, W.K. 1992: Phase II study of cisplatin, ifosfamide, and etoposide combination for advanced non-small cell lung cancer: final report Seminars in Oncology 19(6 Suppl. 12): 58-63
Eagan, R.T.; Lee, R.E.; Frytak, S.; Scott, M.; Ingle, J.N.; Creagan, E.T.; Nichols, W.C. 1981: Thoracic radiation therapy and Adriamycin/cisplatin-containing chemotherapy for locally advanced non-small-cell lung cancer Cancer Clinical Trials 4(4): 381-388
Kosmidis, P.A.; Samantas, E.; Fountzilas, G.; Pavlidis, N.; Apostolopoulou, F.; Skarlos, D. 1994: Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase IIi study. Hellenic Cooperative Oncology Group for Lung Cancer Trials Seminars in Oncology 21(3 Suppl 6: 23-30
Nakano, K.; Yamamoto, M.; Iwamoto, H.; Hiramoto, T. 2003: Daily low-dose cisplatin plus concurrent high-dose thoracic radiotherapy in elderly patients with locally advanced unresectable non-small-cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(9): 1283-1287
Khuri, F.R. 2002: Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy Oncology 16(6 Suppl 6: 53-62
Yokoyama, A. 1999: Gemcitabine hydrochloride is a new anti-cancer agent which will be available in the patients with non-small cell lung cancer (NSCLC) in Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 26(7): 908-915
Gridelli, C.; Frontini, L.; Barletta, E.; Rossi, A.; Barzelloni, M.L.; Scognamiglio, F.; Guida, C.; Gatani, T.; Fiore, F.; De Bellis, M.; Marfella, A.; Manzione, L. 2000: Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non small cell lung cancer. A phase II study and review of the literature Anticancer Research 20(2b): 1077-1084